ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Th XEN-OAL is actually the world’s first frame-lock folding knife with an aluminum handle. Yep — to our knowledge (following some research), that’s never been done before. Bona fides aside, the two ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025. With explosive deals out of the way, news from ...

AbbVie leaders are “disappointed” with poor results from a schizophrenia drug the company acquired last year that led to a $3.5 billion impairment charge, but they say they aren’t completely ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

AbbVie (NYSE:ABBV) is facing turbulence after its experimental schizophrenia drug, emraclidine, flopped in two mid-stage trials. The drug, picked up in AbbVie's $8.7 billion acquisition of Cerevel ...

AbbVie has a 12 month low of $153.58 and a 12 month high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54.

Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...